Reprogrammed Cell‐based Therapy for Liver Disease: From Lab to Clinic
A large number of patients are affected by liver dysfunction worldwide. Liver transplantation is the only efficient treatment in a variety of enduring liver disorders including inherent and end-stage liver diseases. The generation of human functional hepatocytes in high quantities for liver cell the...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Troika Publisher
2017-02-01
|
| Series: | Journal of Renal and Hepatic Disorders |
| Online Access: | https://jrenhep.com/index.php/jrenhep/article/view/6 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849397825464434688 |
|---|---|
| author | Amir Mehdizadeh Masoud Darabi |
| author_facet | Amir Mehdizadeh Masoud Darabi |
| author_sort | Amir Mehdizadeh |
| collection | DOAJ |
| description | A large number of patients are affected by liver dysfunction worldwide. Liver transplantation is the only efficient treatment in a variety of enduring liver disorders including inherent and end-stage liver diseases. The generation of human functional hepatocytes in high quantities for liver cell therapy is an important goal for ongoing therapies in regenerative medicine. Reprogrammed cells are considered as a promising and unlimited source of hepatocytes, mainly because of their expected lack of immunogenicity and minimized ethical concerns in clinical applications. Despite gained advances in the reprogramming of somatic cells to functional hepatocytes in vitro, production of primary adult hepatocytes that can proliferate in vivo still remains inaccessible. As part of efforts toward translation of cell reprogramming science into clinical practice, more careful cell selection strategies should be integrated into improvement of dedifferentiation and redifferentiation protocols, especially in precision medicine where gene correction is needed. Furthermore, advances in cellular reprogramming highlight the need for developing and evaluating novel standards addressing clinical research interests in this field. |
| format | Article |
| id | doaj-art-cae6525143164d06962e48fccf9ee7da |
| institution | Kabale University |
| issn | 2207-3744 |
| language | English |
| publishDate | 2017-02-01 |
| publisher | Troika Publisher |
| record_format | Article |
| series | Journal of Renal and Hepatic Disorders |
| spelling | doaj-art-cae6525143164d06962e48fccf9ee7da2025-08-20T03:38:49ZengTroika PublisherJournal of Renal and Hepatic Disorders2207-37442017-02-011110.15586/jrenhep.2017.64Reprogrammed Cell‐based Therapy for Liver Disease: From Lab to ClinicAmir Mehdizadeh0Masoud Darabi1Liver and Gastrointestinal Diseases Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.- Stem Cell Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. - Department of Biochemistry and Clinical Laboratories, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, IranA large number of patients are affected by liver dysfunction worldwide. Liver transplantation is the only efficient treatment in a variety of enduring liver disorders including inherent and end-stage liver diseases. The generation of human functional hepatocytes in high quantities for liver cell therapy is an important goal for ongoing therapies in regenerative medicine. Reprogrammed cells are considered as a promising and unlimited source of hepatocytes, mainly because of their expected lack of immunogenicity and minimized ethical concerns in clinical applications. Despite gained advances in the reprogramming of somatic cells to functional hepatocytes in vitro, production of primary adult hepatocytes that can proliferate in vivo still remains inaccessible. As part of efforts toward translation of cell reprogramming science into clinical practice, more careful cell selection strategies should be integrated into improvement of dedifferentiation and redifferentiation protocols, especially in precision medicine where gene correction is needed. Furthermore, advances in cellular reprogramming highlight the need for developing and evaluating novel standards addressing clinical research interests in this field.https://jrenhep.com/index.php/jrenhep/article/view/6 |
| spellingShingle | Amir Mehdizadeh Masoud Darabi Reprogrammed Cell‐based Therapy for Liver Disease: From Lab to Clinic Journal of Renal and Hepatic Disorders |
| title | Reprogrammed Cell‐based Therapy for Liver Disease: From Lab to Clinic |
| title_full | Reprogrammed Cell‐based Therapy for Liver Disease: From Lab to Clinic |
| title_fullStr | Reprogrammed Cell‐based Therapy for Liver Disease: From Lab to Clinic |
| title_full_unstemmed | Reprogrammed Cell‐based Therapy for Liver Disease: From Lab to Clinic |
| title_short | Reprogrammed Cell‐based Therapy for Liver Disease: From Lab to Clinic |
| title_sort | reprogrammed cell based therapy for liver disease from lab to clinic |
| url | https://jrenhep.com/index.php/jrenhep/article/view/6 |
| work_keys_str_mv | AT amirmehdizadeh reprogrammedcellbasedtherapyforliverdiseasefromlabtoclinic AT masouddarabi reprogrammedcellbasedtherapyforliverdiseasefromlabtoclinic |